A recent single-arm phase II trial evaluated consolidative stereotactic radiotherapy in 61 patients with metastatic EGFR-mutated NSCLC who had oligo-residual disease after first-line third-generation EGFR-TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.